Helmy Siragy headshot
HS

Helmy M. Siragy

Professor
Unit: School of Medicine
Department: Department of Medicine, Endocrinology and Metabolism
Office location and address
UVA Medical Park Zion Crossroads
450 Ray C Hunt Dr
Charlottesville, Virginia 22903
Education
Tanta University, Egypt, 1977, MD
Residency, Internal Medicine, University of Texas/Galveston
Fellowship, Endocrinology and Hypertension, University of Texas Health Sciences Center, San Antonio; Endocrinology and Hypertension, University of Virginia
Biography

Helmy M. Siragy, M.D., FACP, FAHA is the Harrison Distinguished Chair of Excellence in Medical Education and Professor of Medicine and Endocrinology. An international expert on subjects related to hypertension, Dr. Siragy was the first to discover that stimulation of angiotensin AT2 receptor leads to generation of nitric oxide. Siragy has authored more than 300 medical journal articles and abstracts, and numerous medical textbook chapters, including a chapter on the kidney and the renin angiotensin system in the Braunwald Atlas of Heart Diseases; a chapter on angiotensin and diabetic nephropathy in Harrison's on-line textbook of Medicine; and a chapter on the angiotensin receptor in Hypertension: A Companion to Brenner. Dr Siragy's primary research interests are in the areas of the renin-angiotensin system, cardiac ischemia, diabetic nephropathy and (Pro)Renin receptor. 


Dr. Siragy is a fellow of the American College of Physicians and the American Heart Association, and a member of numerous national and international endocrine and hypertension societies. He serves as a grant reviewer for the National Institutes of Health and the American Heart Association, among other organizations, and is on the editorial boards of journals in the areas of hypertension, endocrinology, and vascular biology. He edits the section on Antihypertensive Agents: Mechanisms of Drug Action for the journals Current Hypertension Reports and Current Hypertension Reviews.

(Pro)renin Receptor Regulates Autophagy in Diabetic Kidney Disease
Source: U.S. NIH Heart, Lung, And Blood Institute
July 14, 2017 – June 30, 2022
(Pro)renin receptor mediates obesity induced hypertension
Source: U.S. NIH Institute of Diabetes & Digestive & Kidne
August 17, 2017 – May 31, 2022
MD-INMD PRR Promotes Obesity Related Hypertension via alpha-ENaC - Fellowship on behalf of Silas Culver
Source: U.S. NIH Institute of Diabetes & Digestive & Kidne
July 01, 2017 – June 30, 2019
MD-INMD-EN (Pro)renin receptor and renovascular hypertension
Source: U.S. NIH Institute of Diabetes & Digestive & Kidne
May 01, 2012 – April 30, 2018
MD-INMD-HMS7A-R01PRORENIN/R01HL091535
Source: U.S. NIH Heart, Lung, And Blood Institute
August 01, 2013 – August 09, 2017
Telmisartan and Metabolic Syndrome
Source: Boehringer Ingelheim International GmbH
February 01, 2011 – December 31, 2016
MD-INMD-HMS7A-R01PRORENIN
Source: U.S. NIH Heart, Lung, And Blood Institute
August 01, 2013 – June 30, 2016
(Pro)renin receptor and renovascular hypertension
Source: U.S. NIH Institute of Diabetes & Digestive & Kidne
May 01, 2012 – April 30, 2016
Prorenin Receptor Mediates Early Changes in Diabetic Kidney
Source: U.S. NIH Heart, Lung, And Blood Institute
January 01, 2008 – June 30, 2013
MD-INMD Role of Combined Aliskiren and Amiodopine in Diabetic Nephropathy
Source: Novartis Pharmaceuticals Corporation
May 18, 2009 – June 30, 2013